vrsa

Ceftobiprole (Ro 63-9141) is a broad-spectrum cephalosporin with activity against Methicillin-resistant staphylococcus aureus (MRSA; MIC90: 2 μg/mL).

Pristinamycin, synthesized by Streptomyces pristinaespiralis, is an orally administered antibiotic resembling streptogramin, comprising two distinct components: Pristinamycin I (PI) and Pristinamycin II (PII). This compound exhibits a high efficacy against various antibiotic-resistant pathogens, especially Gram-positive bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant S. aureus (VRSA), and Enterococcus faecium (VREF) [1].

14-methyl Pentadecanoic acid methyl ester is a methylated fatty acid methyl ester that has been found in S. zeai sea sponges as the fatty acyl component of zeamide, A. indica leaf extract, and C. vulgaris and H. pluvialis microalgae. It is a major component of the vancomycin-induced biofilm produced by vancomycin-resistant S. aureus (VRSA). 14-methyl Pentadecanoic acid methyl ester has been used as a standard for the quantification of 14-methyl pentadecanoic acid in various foods by GC-MS.

Antibacterial agent 75 (compound 24) possesses antibacterial properties. Its notable attribute is the ability to re-sensitize VRSA (Vancomycin-Resistant Staphylococcus aureus) strains to vancomycin, as reported in reference [1].

NusB-IN-1 (Compound 22r) is a highly effective bacterial rRNA synthesis inhibitor, administered orally. It exhibits potent antimicrobial activity against MRSA and VRSA [1].

Ceftobiprole medocaril sodium (BAL5788) is a parenteral prodrug of Ceftobiprole, a pyrrolidinone cephalosporin administered intravenously. As a broad-spectrum cephalosporin, Ceftobiprole exhibits high in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococci (VRSA), and penicillin-resistant Streptococci. Additionally, it is effective in inhibiting both gram-positive and gram-negative pathogens.

AVX 13616, Avexa's leading antibacterial candidate, demonstrates significant in vivo antibacterial efficacy, especially against drug-resistant Staphylococcus pathogens, with an IC50 value of 2-4 µg/ml (MICs) and is targeted as an antibacterial agent. Comparable in activity to mupirocin within a nasal decolonization model, AVX13616 necessitated only a single application for effectiveness. This compound, alongside others, exhibited broad-spectrum antibacterial action, achieving MICs of 2-4 micrograms per milliliter against various isolates, including S. aureus, coagulase-negative staphylococci, enterococci, MRSA, VISA, and VRSA. Aimed for topical use and the treatment of wound infection or catheter-related infections, a solitary 5% (w/w) AVX13616 application (roughly equivalent to 2% mupirocin) proved as efficacious as twice-daily 2% mupirocin over five days in decolonizing MRSA in mice.

Ceftobiprole medocaril (BAL5788) is the parenteral prodrug of Ceftobiprole. Ceftobiprole is a broad-spectrum cephalosporin with activity against Methicillin-resistant staphylococcus aureus (MRSA).